(888) 39-MERCY
Wisconsin & Illinois

Trials Available at Mercyhealth Cancer Care


Mercyhealth is seeking healthy volunteers to provide six vials of blood and some health information such as name, date of birth, and family medical background. Blood samples from healthy volunteers will be compared to cancer patient volunteers in order to develop a blood test designed to detect multiple types of cancer at the earliest stage possible. After completion of the study you will be compensated for your participation.

If interested, please email oncologyclinicaltrials@mhemail.org or call the Mercyhealth Cancer Center—Janesville Research Office at (608) 756-6695 or Mercyhealth Cancer Center—Rockford Research Office at
(815) 971-5858.


A011801 – The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

NRG BR004 – NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

NRG BR003– A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without  Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Breast Cancer

SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Rumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

Colon and Rectum

NRG GI004 – Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

S1613– A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification


EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non?Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature?driven Analysis

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Pancreatic Surveillance

EA2185Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs


PCR0002 – Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer

Multiple Cancer Sites

EAY131 – Molecular Analysis for Therapy Choice (MATCH)

Exact Sciences/ICON – Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid